List of works - Hensin Tsao

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

scientific article published on 25 January 2016

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma ⬇️

scientific article published on April 24, 2013

Commentary: Molecular testing in melanoma.

scientific article published on 16 February 2014

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma

scientific article published on June 2014

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma

scientific article

KIT and Melanoma: Biological Insights and Clinical Implications

scientific article published on 01 July 2020

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

scientific article

MITF Modulates Therapeutic Resistance through EGFR Signaling

scientific article published on 19 March 2015

Melanoma: New Insights and New Therapies ⬇️

scientific article published on January 5, 2012

Molecular profiling reveals low- and high-grade forms of primary melanoma

scientific article

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

scientific article published in May 2015

Molecular therapeutic approaches to melanoma

scientific article published on 20 February 2010

New Insights into Melanoma Tumor Syndromes

scientific article published in 2022

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

scientific article published on 15 June 2010

Targeting the RAS pathway in melanoma

scientific article published on 30 September 2011

The state of melanoma: challenges and opportunities

scientific article

Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth ⬇️

scientific article published on June 27, 2013

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition

scientific article published on 13 October 2011

List of works by Hensin Tsao

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma ⬇️

Commentary: Molecular testing in melanoma.

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma

KIT and Melanoma: Biological Insights and Clinical Implications

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

MITF Modulates Therapeutic Resistance through EGFR Signaling

Melanoma: New Insights and New Therapies ⬇️

Molecular profiling reveals low- and high-grade forms of primary melanoma

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

Molecular therapeutic approaches to melanoma

New Insights into Melanoma Tumor Syndromes

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

Targeting the RAS pathway in melanoma

The state of melanoma: challenges and opportunities

Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth ⬇️

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition